Production of a heterozygous exon skipping model of common marmosets using gene-editing technology.


Journal

Lab animal
ISSN: 1548-4475
Titre abrégé: Lab Anim (NY)
Pays: United States
ID NLM: 0417737

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 10 07 2023
accepted: 29 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: aheadofprint

Résumé

Nonhuman primates (NHPs), which are closely related to humans, are useful in biomedical research, and an increasing number of NHP disease models have been reported using gene editing. However, many disease-related genes cause perinatal death when manipulated homozygously by gene editing. In addition, NHP resources, which are limited, should be efficiently used. Here, to address these issues, we developed a method of introducing heterozygous genetic modifications into common marmosets by combining Platinum transcription activator-like effector nuclease (TALEN) and a gene-editing strategy in oocytes. We succeeded in introducing the heterozygous exon 9 deletion mutation in the presenilin 1 gene, which causes familial Alzheimer's disease in humans, using this technology. As a result, we obtained animals with the expected genotypes and confirmed several Alzheimer's disease-related biochemical changes. This study suggests that highly efficient heterozygosity-oriented gene editing is possible using TALEN and oocytes and is an effective method for producing genetically modified animals.

Identifiants

pubmed: 39215182
doi: 10.1038/s41684-024-01424-0
pii: 10.1038/s41684-024-01424-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP20dm0207065
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : 24zf0127007h0003
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP20dm0207001
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : JP21H04756

Informations de copyright

© 2024. The Author(s).

Références

Sasaki, E. et al. Generation of transgenic non-human primates with germline transmission. Nature 459, 523–527 (2009).
pubmed: 19478777 doi: 10.1038/nature08090
Sato, K. et al. Generation of a nonhuman primate model of severe combined immunodeficiency using highly efficient genome editing. Cell Stem Cell 19, 127–138 (2016).
pubmed: 27374787 doi: 10.1016/j.stem.2016.06.003
Tsukiyama, T. et al. Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease. Nat. Commun. 10, 5517 (2019).
pubmed: 31822676 pmcid: 6904451 doi: 10.1038/s41467-019-13398-6
Zhou, Y. et al. Atypical behaviour and connectivity in SHANK3-mutant macaques. Nature 570, 326–331 (2019).
pubmed: 31189958 doi: 10.1038/s41586-019-1278-0
Kim, Y. G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl Acad. Sci. USA 93, 1156–1160 (1996).
pubmed: 8577732 pmcid: 40048 doi: 10.1073/pnas.93.3.1156
Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757–761 (2010).
pubmed: 20660643 pmcid: 2942870 doi: 10.1534/genetics.110.120717
Doyle, E. L. et al. TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res. 40, W117–W122 (2012).
pubmed: 22693217 pmcid: 3394250 doi: 10.1093/nar/gks608
Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
pubmed: 23287718 pmcid: 3795411 doi: 10.1126/science.1231143
Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).
pubmed: 22745249 pmcid: 6286148 doi: 10.1126/science.1225829
Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
pubmed: 23287722 pmcid: 3712628 doi: 10.1126/science.1232033
Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).
pubmed: 29160308 pmcid: 5726555 doi: 10.1038/nature24644
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).
pubmed: 27096365 pmcid: 4873371 doi: 10.1038/nature17946
Nishida, K. et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, aaf8729 (2016).
pubmed: 27492474 doi: 10.1126/science.aaf8729
Miller, J. C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143–148 (2011).
pubmed: 21179091 doi: 10.1038/nbt.1755
Sakuma, T. et al. Repeating pattern of non-RVD variations in DNA-binding modules enhances TALEN activity. Sci. Rep. 3, 3379 (2013).
pubmed: 24287550 pmcid: 3843162 doi: 10.1038/srep03379
Kumita, W. et al. Efficient generation of knock-in/knock-out marmoset embryo via CRISPR/Cas9 gene editing. Sci. Rep. 9, 12719 (2019).
pubmed: 31481684 pmcid: 6722079 doi: 10.1038/s41598-019-49110-3
Dickinson, M. E. et al. High-throughput discovery of novel developmental phenotypes. Nature 537, 508–514 (2016).
pubmed: 27626380 pmcid: 5295821 doi: 10.1038/nature19356
Winblad, B. et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 15, 455–532 (2016).
pubmed: 26987701 doi: 10.1016/S1474-4422(16)00062-4
Crook, R. et al. A variant of Alzheimer’s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat. Med. 4, 452–455 (1998).
pubmed: 9546792 doi: 10.1038/nm0498-452
Iwatsubo, T. et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 13, 45–53 (1994).
pubmed: 8043280 doi: 10.1016/0896-6273(94)90458-8
Scheuner, D. et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 2, 864–870 (1996).
pubmed: 8705854 doi: 10.1038/nm0896-864
Tomita, T. et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc. Natl Acad. Sci. USA 94, 2025–2030 (1997).
pubmed: 9050898 pmcid: 20036 doi: 10.1073/pnas.94.5.2025
Cacace, R., Sleegers, K. & Van Broeckhoven, C. Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement. 12, 733–748 (2016).
pubmed: 27016693 doi: 10.1016/j.jalz.2016.01.012
Prihar, G. et al. Alzheimer disease PS-1 exon 9 deletion defined. Nat. Med. 5, 1090 (1999).
pubmed: 10502791 doi: 10.1038/13383
Thinakaran, G. et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17, 181–190 (1996).
pubmed: 8755489 doi: 10.1016/S0896-6273(00)80291-3
Yang, M. et al. Optimized two-step electroporation process to achieve efficient nonviral-mediated gene insertion into primary T cells. FEBS Open Bio 12, 38–50 (2022).
pubmed: 34510816 doi: 10.1002/2211-5463.13292
Liang, X. et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J. Biotechnol. 208, 44–53 (2015).
pubmed: 26003884 doi: 10.1016/j.jbiotec.2015.04.024
Tu, Z. et al. Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos. Sci. Rep. 7, 42081 (2017).
pubmed: 28155910 pmcid: 5290468 doi: 10.1038/srep42081
Su, X. et al. Production of non-mosaic genome edited porcine embryos by injection of CRISPR/Cas9 into germinal vesicle oocytes. J. Genet. Genomics 46, 335–342 (2019).
pubmed: 31378649 doi: 10.1016/j.jgg.2019.07.002
Su, X. et al. Effective generation of maternal genome point mutated porcine embryos by injection of cytosine base editor into germinal vesicle oocytes. Sci. China Life Sci. 63, 996–1005 (2020).
pubmed: 31974864 doi: 10.1007/s11427-019-1611-1
Saito, T. et al. Potent amyloidogenicity and pathogenicity of Aβ43. Nat. Neurosci. 14, 1023–1032 (2011).
pubmed: 21725313 doi: 10.1038/nn.2858
Sasaguri, H. et al. Introduction of pathogenic mutations into the mouse Psen1 gene by base editor and target-AID. Nat. Commun. 9, 2892 (2018).
pubmed: 30042426 pmcid: 6057936 doi: 10.1038/s41467-018-05262-w
Donoviel, D. B. et al. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev. 13, 2801–2810 (1999).
pubmed: 10557208 pmcid: 317124 doi: 10.1101/gad.13.21.2801
Banas, K. et al. Exon skipping induced by CRISPR-directed gene editing regulates the response to chemotherapy in non-small cell lung carcinoma cells. Gene Ther. 29, 357–367 (2022).
pubmed: 35314779 pmcid: 9203268 doi: 10.1038/s41434-022-00324-7
Chemello, F. et al. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci. Adv. 7, eabg4910 (2021).
pubmed: 33931459 pmcid: 8087404 doi: 10.1126/sciadv.abg4910
Sui, T. et al. CRISPR-induced exon skipping is dependent on premature termination codon mutations. Genome Biol. 19, 164 (2018).
pubmed: 30333044 pmcid: 6193291 doi: 10.1186/s13059-018-1532-z
Uddin, B., Chen, N. P., Panic, M. & Schiebel, E. Genome editing through large insertion leads to the skipping of targeted exon. BMC Genomics 16, 1082 (2015).
pubmed: 26691863 pmcid: 4687116 doi: 10.1186/s12864-015-2284-8
Zhu, X. X. et al. Adenine base-editing-mediated exon skipping induces gene knockout in cultured pig cells. Biotechnol. Lett. 44, 59–76 (2022).
pubmed: 34997407 doi: 10.1007/s10529-021-03214-x
Quiroz, Y. T. et al. Brain imaging and blood biomarker abnormalities in children with autosomal dominant Alzheimer disease: a cross-sectional study. JAMA Neurol. 72, 912–919 (2015).
pubmed: 26121081 pmcid: 4625544 doi: 10.1001/jamaneurol.2015.1099
Steiner, H. et al. The biological and pathological function of the presenilin-1 Δexon 9 mutation is independent of its defect to undergo proteolytic processing. J. Biol. Chem. 274, 7615–7618 (1999).
pubmed: 10075646 doi: 10.1074/jbc.274.12.7615
Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 367, 795–804 (2012).
pubmed: 22784036 pmcid: 3474597 doi: 10.1056/NEJMoa1202753
Perez-Tur, J. et al. A mutation in Alzheimer’s disease destroying a splice acceptor site in the presenilin-1 gene. NeuroReport 7, 297–301 (1995).
pubmed: 8742474 doi: 10.1097/00001756-199512000-00071
Geula, C., Nagykery, N. & Wu, C. K. Amyloid-β deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathol. 103, 48–58 (2002).
pubmed: 11837747 doi: 10.1007/s004010100429
Sakuma, T. et al. Efficient TALEN construction and evaluation methods for human cell and animal applications. Genes Cells 18, 315–326 (2013).
pubmed: 23388034 doi: 10.1111/gtc.12037
Kurotaki, Y. & Sasaki, E. Practical reproductive techniques for the common marmoset. J. Mamm. Ova Res. 34, 3–12 (2017).
doi: 10.1274/032.034.0103
Takahashi, T. et al. Birth of healthy offspring following ICSI in in vitro-matured common marmoset (Callithrix jacchus) oocytes. PLoS One 9, e95560 (2014).
pubmed: 24751978 pmcid: 3994092 doi: 10.1371/journal.pone.0095560
Tomioka, I., Takahashi, T., Shimada, A., Yoshioka, K. & Sasaki, E. Birth of common marmoset (Callithrix jacchus) offspring derived from in vitro-matured oocytes in chemically defined medium. Theriogenology 78, 1487–1493 (2012).
pubmed: 22925648 doi: 10.1016/j.theriogenology.2012.06.024
Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595–599 (2010).
pubmed: 20495550 pmcid: 2919230 doi: 10.1038/nbt.1641
Takabayashi, S., Suzuki, Y. & Katoh, H. Development of a modified artificial insemination technique combining penile vibration stimulation and the swim-up method in the common marmoset. Theriogenology 83, 1304–1309.e2 (2015).
pubmed: 25732321 doi: 10.1016/j.theriogenology.2015.01.017

Auteurs

Kenya Sato (K)

Department of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.
Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.

Hiroki Sasaguri (H)

Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Dementia Pathophysiology Collaboration Unit, RIKEN Center for Brain Science, Wako, Japan.

Wakako Kumita (W)

Department of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.
Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.

Tetsushi Sakuma (T)

Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Japan.

Tomoe Morioka (T)

Department of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.

Kenichi Nagata (K)

Department of Functional Anatomy and Neuroscience, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Takashi Inoue (T)

Department of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.

Yoko Kurotaki (Y)

Center of Basic Technology in Marmoset, Central Institute for Experimental Animals, Kawasaki, Japan.

Naomi Mihira (N)

Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.

Michihira Tagami (M)

Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Ri-Ichiroh Manabe (RI)

Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Kokoro Ozaki (K)

Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Yasushi Okazaki (Y)

Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Takashi Yamamoto (T)

Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Japan.

Makoto Suematsu (M)

Department of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.
WPI-Bio2Q Research Center, Keio University, Tokyo, Japan.

Takaomi C Saido (TC)

Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan. takaomi.saido@riken.jp.

Erika Sasaki (E)

Department of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan. esasaki@ciea.or.jp.
Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan. esasaki@ciea.or.jp.

Classifications MeSH